Badrilla Ltd, founded in 2003, is an established life science company providing high quality products for the molecular cardiovascular researcher located within major pharmaceutical, biotech, and academic establishments worldwide... Read More
Professor Colyer established Badrilla in 2003, combining substantive entrepeneurial experience with a deep understanding of the cardiovascular research field. The company has grown organically, reinvesting revenues into... Read More
Badrilla provides a comprehensive range of research products to study ryanodine receptor function in health and disease. We have made the original and best antibodies to phosphorylated RYR2 (S2808, S2814, S2030). These are the most widely cited tools used by researchers to follow RYR2 phosphorylation at individual sites, and we display the citations for each antibody on the product page –data that are wholly independent of Badrilla and provided by CiteAb. Leaders in the field are confident of the quality of these antibodies as described in peer-reviewed articles available (Huke & Bers (2008) Biochem. Biophys. Res. Comm. 376, 80-85).
We have bioactive peptides that mimic dysfunction ofRYR2 normally seen in CPVT-mutant channels(DPc10), fluorescent versions of these. These peptides turn a normal RYR2 channel into an abnormal (CPVT-like) channel and we may facilitate your exploration of disease conditions.Polyclonal antibody specific to RYR2 phospho-Ser2030.
Currently Shopping by:
You have no items to compare.
.
DISCLAIMER: Products for research use only (RUO) and are not intended for diagnostic or therapeutic use.